Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study.

Journal:

Annals of Internal Medicine

Published:

2025-12-23

DOI:

10.7326/annals-25-01939

Affiliations:

16

Authors:

23

Go to article

Institutions	Authors	Share
Gilead, United States of America (USA)	6.000000	0.26
Merck - Rahway, United States of America (USA)	3.000000	0.13
Community Health Care, United States of America (USA)	1.000000	0.04
Ruane Clinical Research Group Inc., United States of America (USA)	1.000000	0.04
Cambridge Health Alliance (CHA), United States of America (USA)	1.000000	0.04
Prism Health North Texas, United States of America (USA)	1.000000	0.04
Infectious Disease Care (ID CARE), United States of America (USA)	1.000000	0.04
The University of North Carolina at Chapel Hill (UNC), United States of America (USA)	1.000000	0.04
Midway Immunology Research Center, United States of America (USA)	1.000000	0.04
Emory University, United States of America (USA)	1.000000	0.04
The George Washington University (GW), United States of America (USA)	1.000000	0.04
Gordon E. Crofoot MD, PA, United States of America (USA)	1.000000	0.04
Metro Infectious Disease Consultants, United States of America (USA)	1.000000	0.04
Central Texas Clinical Research, United States of America (USA)	1.000000	0.04
North Texas Infectious Diseases Consultants (NTIDC), United States of America (USA)	1.000000	0.04
University of Miami (UM), United States of America (USA)	1.000000	0.04

Interested in Clinical Sciences?